Your browser doesn't support javascript.
loading
Applicability of the GAIA Maternal and Neonatal Outcome Case Definitions for the Evaluation of Adverse Events Following Vaccination in Pregnancy in High-income Countries.
Watson, Gabriella; Dodd, Caitlin; Munoz, Flor M; Eckert, Linda O; Jones, Christine E; Buttery, Jim P; Yildirim, Inci B; Kachikis, Alisa; Heath, Paul T; Schlaudecker, Elizabeth P; Bond, Nanette H; Santarcangelo, Patricia L; Wilcox, Christopher R; Bellamy, Karen; Elmontser, Mohnd; Sienas, Laura; Simon, Rebecca; Khalil, Asma; Townsend, Rosemary; Sturkenboom, Miriam; Black, Steve.
Afiliação
  • Watson G; From the Department of Paediatric Infectious Diseases and Immunology, University Hospital Southampton, Southampton, United Kingdom.
  • Dodd C; Julius Global Health, Universitair Medisch Centrum, Utrecht, The Netherlands.
  • Munoz FM; Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.
  • Eckert LO; Department of Obstetrics and Gynecology, and Department of Global Health, Seattle, Washington.
  • Jones CE; Faculty of Medicine and Institute for Life Sciences, University of Southampton and NIHR Southampton Clinical Research Facility, Southampton, United Kingdom.
  • Buttery JP; Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Yildirim IB; Infection and Immunity, Monash Children's Hospital, Monash Health, Department of Paediatrics, Monash University, Melbourne, Australia.
  • Kachikis A; Yale University School of Medicine, Department of Pediatrics, Section of Infectious Diseases and Global Health.
  • Heath PT; Yale Institute of Global Health, New Haven, Connecticut.
  • Schlaudecker EP; Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, University of Washington, Seattle, Washington.
  • Bond NH; From the Department of Paediatric Infectious Diseases and Immunology, University Hospital Southampton, Southampton, United Kingdom.
  • Santarcangelo PL; Julius Global Health, Universitair Medisch Centrum, Utrecht, The Netherlands.
  • Wilcox CR; Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.
  • Bellamy K; Department of Obstetrics and Gynecology, and Department of Global Health, Seattle, Washington.
  • Elmontser M; Faculty of Medicine and Institute for Life Sciences, University of Southampton and NIHR Southampton Clinical Research Facility, Southampton, United Kingdom.
  • Sienas L; Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
  • Simon R; Infection and Immunity, Monash Children's Hospital, Monash Health, Department of Paediatrics, Monash University, Melbourne, Australia.
  • Khalil A; Yale University School of Medicine, Department of Pediatrics, Section of Infectious Diseases and Global Health.
  • Townsend R; Yale Institute of Global Health, New Haven, Connecticut.
  • Sturkenboom M; Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, University of Washington, Seattle, Washington.
  • Black S; Vaccine Institute, St George's, University of London, London, United Kingdom.
Pediatr Infect Dis J ; 40(12): 1127-1134, 2021 12 01.
Article em En | MEDLINE | ID: mdl-34596623
BACKGROUND: The Brighton Collaboration Global Alignment of Immunization Safety in Pregnancy (GAIA) project developed case definitions for the assessment of adverse events in mothers and infants following maternal immunization. This study evaluated the applicability of these definitions to data collected in routine clinical care and research trial records across 7 sites in high-resource settings. METHODS: Data collection forms were designed and used to retrospectively abstract the key elements of the GAIA definitions from records for 5 neonatal and 5 maternal outcomes, as well as gestational age. Level of diagnostic certainty was assessed by the data abstractor and an independent clinician, and then verified by Automated Brighton Case logic. The ability to assign a level of diagnostic certainty for each outcome and the positive predictive value (PPV) for their respective ICD-10 codes were evaluated. RESULTS: Data from 1248 case records were abstracted: 624 neonatal and 622 maternal. Neonatal outcomes were most likely to be assessable and assigned by the level of diagnostic certainty. PPV for preterm birth, low birth weight, small for gestational age and respiratory distress were all above 75%. Maternal outcomes for preeclampsia and fetal growth restriction showed PPV over 80%. However, microcephaly (neonatal outcome) and dysfunctional labor (maternal outcome) were often nonassessable, with low PPVs. CONCLUSIONS: The applicability of GAIA case definitions to retrospectively ascertain and classify maternal and neonatal outcomes was variable among sites in high-resource settings. The implementation of the case definitions is largely dependent on the type and quality of documentation in clinical and research records in both high- and low-resource settings. While designed for use in the prospective evaluation of maternal vaccine safety, the GAIA case definitions would likely need to be specifically adapted for observational studies using alternative sources of data, linking various data sources and allowing flexibility in the ascertainment of the elements and levels of certainty of the case definition.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Países Desenvolvidos / Vacinação Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Países Desenvolvidos / Vacinação Idioma: En Ano de publicação: 2021 Tipo de documento: Article